Anzeige
Mehr »
Sonntag, 08.02.2026 - Börsentäglich über 12.000 News
Der Shakeout: Silber hat genau das getan, was echte Bullenmärkte immer tun - es hat die Touristen abgeschüttelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
17 Leser
Artikel bewerten:
(0)

Cellular Imaging Market (single cell analysis/Live cell imaging)

DUBLIN, Oct. 8, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Cellular Imaging Market (single cell analysis/Live cell imaging)" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Single cell analysis plays an important role in genomics, proteomics, transcriptomics and epigenomics at the single cell level. It provides an ultra-sensitive tool to explicate specific molecular mechanisms and pathways and reveal the nature of cell heterogenecity. Hospitals, academic and government bodies, as well as pharmaceutical and biotechnology companies are mounting their focus on using cell analysis as a prevailing tool in research, drug discovery and diagnosis. The cell analysis market is mainly segmented into consumables and instruments. The consumables include reagents, assay plates and microplates. The instrument segment comprises of microscopes, flow cytometer, spectrophotometer, quantitative polymerase chain reaction (QPCR), microfluidic devices, cell counters, high content screening (HCS) systems and cell microarrays.

Among the cell analysis products, the consumables market dominated the instruments market by occupying a largest share of more than 60%. However, the cell analysis instruments market is expected to grow at the highest CAGR. Geographical wise North America is the largest market, followed by Europe and Asia. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the cell analysis market. Growth in the Asian market is attributed to government for its support in establishing innovative screening technologies and increasing demand for outsourcing of drug discovery services.

The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment.

The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. The key players in the global cell analysis market include Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation.

Key Topics Covered:

1. Executive summary

2. Introduction

3. Market Analysis

4. Single cell analysis market by technology

5. Single cell analysis market by products

6. Single cell analysis market by field of study

7. Single cell analysis market by applications

8. Single cell analysis market by end users

9. Regional Market Analysis

10. Company Developments

11. Major Company Profiles

Companies Mentioned:

  • Agilent Technologies, Inc.
  • Beckton, Dickinson And Company
  • Danaher Corporation
  • GE Healthcare
  • Merck KGaA
  • Olympus Corpopration
  • Perkinelmer, Inc
  • Promega Corporation
  • Sigma-Aldrich Corporation
  • Thermo Fisher Scientific, Inc.

For more information visit http://www.researchandmarkets.com/research/8r344h/cellular_imaging

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

© 2014 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.